Buffered Injectable DMT Formulations for Improved Shelf-Life
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current injectable solutions of DMT are unstable over longer periods, necessitating immediate preparation or freezing, which limits their clinical applicability.
Innovation Solution
A pharmaceutical formulation comprising a salt of an optionally substituted dimethyltryptamine compound, a separate buffer, and water, with pH values between 3.5 and 6.5 and osmolalities of 250 to 350 mOsm/Kg, enhancing stability and clinical acceptability.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Ease of operation
If DMT is formulated as an injectable solution, then it can be administered clinically, but it degrades quickly and becomes unstable
Solution Approach 1:
The patent applies parameter changes by adjusting the pH of the injectable solution to a specific range (pH 3.0-7.0, preferably pH 4.0-6.0) and controlling the concentration of DMT fumarate (0.1-10 mg/mL). These parameter optimizations stabilize the DMT compound in solution, preventing rapid degradation while maintaining clinical administrability. The buffer system further maintains these parameters during storage.
Solution Approach 2:
The patent creates a composite formulation by combining DMT fumarate salt with a buffer system (such as acetate, citrate, or phosphate buffers) and water for injection. This composite formulation synergistically provides both clinical administrability and enhanced stability, as the buffer components work together with the DMT salt to maintain solution integrity over time.
2Stability of the object's composition
If DMT solution is prepared immediately before use, then it remains stable, but it limits clinical applicability and requires freezing
Solution Approach 1:
The patent applies preliminary action by pre-formulating DMT in a stable injectable solution with optimized pH and buffer systems that can be stored for extended periods without degradation. This eliminates the need for immediate preparation before use, allowing clinicians to have stable DMT solutions ready for administration without requiring freezing or last-minute preparation.
Solution Approach 2:
By changing the formulation parameters (pH to 3.0-7.0, adding buffer systems, controlling DMT concentration), the patent extends the shelf-life of DMT solutions from requiring immediate use to allowing prolonged storage at controlled temperatures, thereby improving clinical efficiency and productivity.
3Ease of operation
If DMT is injected as a salt solution, then it can be administered, but the pH and osmolality must be clinically acceptable
Solution Approach 1:
The patent optimizes formulation parameters by adjusting pH to 3.0-7.0 and osmolality to 250-350 mOsm/kg, which are clinically acceptable ranges for injection. These parameter changes ensure ease of administration while the buffer system and salt selection simplify the overall formulation process.
Solution Approach 2:
The patent uses buffer systems (acetate, citrate, or phosphate buffers) as intermediaries to mediate between the DMT salt and the final injectable solution. These buffers simplify the formulation by automatically maintaining pH within the clinically acceptable range, reducing the complexity of pH adjustment and stabilization.
Data Source
AI summary
Provided herein are pharmaceutical formulations, methods for their production, and uses thereof. The pharmaceutical formulations comprise a salt of an optionally substituted dimethyltryptamine compound, a buffer, which is separate to the salt, and water. The formulations have pH values of from about 3.5 to about 6.5 and osmolalities of about 250 to about 350 mOsm/Kg. Such formulations are suitable for injection, being both stable and clinically acceptable, and have potential uses in the treatment of psychiatric or neurological disorders.